CD274 and non-small cell lung carcinoma: To avoid these possible confounding factors such as different tumor entities or treatment lines and different PD‐L1 expressions, in our work we used a clearly defined population with regard to the tumor entity NSCLC with high PD‐L1 expression of the tumor and evaluated the different therapy modalities with chemoimmunotherapy combination and monoimmunotherapy separately.